Visit EmeritusDX at ACG (Booth 1635) & AAPM&R (Booth 2635) | Explore Our Solutions
Client Services:800-959-2846|Billing:949-374-5019
Gastroenterology Services
GI Biopsies
Gastrointestinal endoscopy and the acquisition of tissue samples are essential for the diagnosis and treatment of various diseases of the digestive system. A range of tissue samples are extracted and are analyzed under a microscope using a Hematoxylin & Eosin stain, and in some cases, immunohistochemical and special stains to identify c
Gastrointestinal endoscopy and the acquisition of tissue samples are essential for the diagnosis and treatment of various diseases of the digestive system. A range of tissue samples are extracted and are analyzed under a microscope using a Hematoxylin & Eosin stain, and in some cases, immunohistochemical and special stains to identify cancerous cell abnormalities. If cancer is present, it can be localized to the exact region from the location of the tissue extraction.
Barrett's Esophagus FISH
This test identifies patients with high risk Barrett’s esophagus that have an increased probability of progression to esophageal cancer. The test employs cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) methodologies, in concert, to differentiate between patients that require aggressive invervention ver
This test identifies patients with high risk Barrett’s esophagus that have an increased probability of progression to esophageal cancer. The test employs cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) methodologies, in concert, to differentiate between patients that require aggressive invervention versus candidates for reduced surveillance. The test can be performed on both biopsies and brushings from patients with Barrett's esophagus. The biomarkers associated with BE FISH can be ordered as a panel (BE FISH+) or individually based on the needs of the ordering physician.
BE FISH+
ABOUT OUR TEST
EmeritusDX BE FISH+ provides a comprehensive approach to evaluating patients with Barrett’s esophagus who may be at increased risk for progression to esophageal adenocarcinoma. By combining cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), BE FISH+ delivers a more complete assessment of morphologic and molecular changes associated with disease progression.
KRAS Therascreen®
ABOUT OUR TEST
The therascreen KRAS is a real-time, qualitative in vitro diagnostic test for the detection of 7 somatic mutations in the KRAS oncogene using a sample of DNA extracted from formalin-fixed, paraffin-embedded (FPPE) non-small cell lung cancer (NSCLC) tissue and colorectal cancer (CRC) tissue.
The therascreen KRAS is an FDA-approved companion diagnostic (CDx) PCR test intended to aid in the identification of NSCLC patients for treatment with LUMAKRAS (sotorasib) or KRAZATI (adagrasib) based on a KRAS G12C Mutation Detected result. In addition, the test is also an FDA-approved CDx test to aid in the selection of patients with CRC who may be eligible for treatment with Erbitux (cetuximab) or Vectibix (panitumumab), based on a KRAS No Mutation Detected test result.
OUR REQUISITION
BRAF Therascreen®
ABOUT OUR TEST
The therascreen BRAF test enables qualitative detection of V600E mutations in the BRAF gene. It is an FDA-approved CDx assay to identify patients with cases of metastatic colorectal cancer for whom treatment with BRAFTOVI (encorafenib) in combination with cetuximab may be appropriate.
OUR REQUISITION
GI Detect™ Comprehensive
ABOUT OUR TEST
GI Detect™ Comprehensive combines rapid molecular testing for gastrointestinal pathogens with two GI health markers, calprotectin and pancreatic elastase. From a single stool sample, it helps identify potential infections while providing insight into intestinal inflammation and
pancreatic function.